Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

Careers

Revolutionizing treatment for patients in need

Actual patients with Demodex blepharitis.

Creating novel therapies, beginning with the eye

XDEMVY® (lotilaner ophthalmic solution) 0.25% is the first and only FDA-approved product for the millions of patients living with Demodex blepharitis.

Learn about XDEMVY

Important Safety Information:
Most common side effects: Most common side effect in clinical trials was stinging and burning in 10% patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please see full Important Safety Information at XDEMVY.com.

Advancing a novel pipeline designed to solve complex problems

We are focused on advancing a robust pipeline designed to address large diseases with limited treatment options.

View our pipeline

What Makes Tarsus Different?

Our scientific approach to creating new categories and our distinct culture are what set us apart.

Discover Tarsus

Our Terms of Use and Privacy Policy have changed.

By clicking accept, you agree that you have read and will abide by these new terms.